Clear cell renal cell carcinoma is by far the most common form of kidney cancer; however, a number of histologically similar tumors are now recognized and considered distinct entities. The Cancer Genome Atlas published data set was queried (http://cbioportal.org) for clear cell renal cell carcinoma tumors lacking VHL gene mutation and chromosome 3p loss, for which whole-slide images were reviewed. Of the 418 tumors in the published Cancer Genome Atlas clear cell renal cell carcinoma database, 387 had VHL mutation, copy number loss for chromosome 3p, or both (93%). Of the remaining, 27/31 had whole-slide images for review. One had 3p loss based on karyotype but not sequencing, and three demonstrated VHL promoter hypermethylation. Nine could be reclassified as distinct or emerging entities: translocation renal cell carcinoma (n = 3), TCEB1 mutant renal cell carcinoma (n = 3), papillary renal cell carcinoma (n = 2), and clear cell papillary renal cell carcinoma (n = 1). Of the remaining, 6 had other clear cell renal cell carcinoma-associated gene alterations (PBRM1, SMARCA4, BAP1, SETD2), leaving 11 specimens, including 2 high-grade or sarcomatoid renal cell carcinomas and 2 with prominent fibromuscular stroma (not TCEB1 mutant). One of the remaining tumors exhibited gain of chromosome 7 but lacked histological features of papillary renal cell carcinoma. Two tumors previously reported to harbor TFE3 gene fusions also exhibited VHL mutation, chromosome 3p loss, and morphology indistinguishable from clear cell renal cell carcinoma, the significance of which is uncertain. In summary, almost all clear cell renal cell carcinomas harbor VHL mutation, 3p copy number loss, or both. Of tumors with clear cell histology that lack these alterations, a subset can now be reclassified as other entities. Further study will determine whether additional entities exist, based on distinct genetic pathways that may have implications for treatment.
molecular characteristics, such as exemplified by translocation renal cell carcinoma and clear cell papillary renal cell carcinoma. 4, 5 It remains to be fully understood, however, whether there are additional renal tumor entities with 'clear cell' histology that warrant classification as unique tumor types with implications for prognosis or targeted treatment. 6, 7 Materials and methods Samples were retrieved from the previously reported Cancer Genome Atlas study on clear cell renal cell carcinoma that was institutional review boardapproved at each participating site. 3 The Cancer Genome Atlas data set for clear cell renal cell carcinoma 3 was queried for alterations of 3p and the VHL gene via http://cbioportal.org, as previously described. 8, 9 Whole-slide images were retrieved from the Cancer Digital Slide Archive (http://cancer.digitalslidearchive.net/) and clinical and pathological information was retrieved from the publically available data set 10 and http://cbiopor tal.org. 8, 9 Original pathology reports that were available were reviewed for diagnosis, comments, immunohistochemical studies, and cytogenetic information, when available. The available sequence data were also analyzed for the presence of gene fusions, using methods previously described. 11 Methylation call data for these samples for the VHL promoter region were compiled from the Cancer Genome Atlas data, which were generated through the Infinium HumanMethylation450 BeadChip assay. 3 
Results
A total of 418 tumors were retrieved from the published Cancer Genome Atlas clear cell renal cell carcinoma dataset that contained both sequencing and copy number data. Of these, 224 were flagged as having VHL mutation or deep deletion. An additional 143 were found to have a 3p arm copy number loss without detection of VHL mutation or deep deletion. Another 20 were found to have decreased copy number for the entire chromosome 3, interpreted as monosomy 3. In total, 387 exhibited VHL mutation, copy number loss for chromosome 3p, or both (93%). Of the remaining 31 tumors, 27 had whole-slide images for review and formed the study cohort. Of these, methylation data were available for 15 of the 27 tumors, of which 5 had only tumor tissue (no normal tissue comparison). From these, 4 of the 15 were noted to have methylation at the VHL promoter site, ranging from 1 to 3 sites. 3 Unique histological characteristics of the study cohort are summarized as follows:
Three of the tumors with intact VHL and 3p25 were recently reported by Malouf et al 12 to be translocation renal cell carcinomas. All three of these tumors had suggestive histology of a translocationassociated renal cell carcinoma, including large nests with calcifications, eosinophilic cells, papillae, and sclerotic stroma (Figures 1a and b) . For one of the three tumors, a karyotype was available as part of the original pathology report, confirming t(X;1)(p11.2; p34). A fourth tumor lacking VHL alteration or 3p loss showed features reminiscent of translocation renal cell carcinoma by morphological review, including hyaline stroma, cells with voluminous cytoplasm, and well-defined cell borders. However, this was not detected to harbor a translocation in the study by Malouf et al 12 or in our own sequence analysis. Interestingly, two tumors reported to have SFPQ-TFE3 translocation in the same study 12 also exhibited VHL mutation, copy number loss for chromosome 3p, and morphology indistinguishable from clear cell renal cell carcinoma. (These were not included in the study denominator of 27 specimens, as they were positive for VHL alteration and copy number 3p loss.) Of these, 1 was also predicted to harbor SFPQ-TFE3 fusion in our own analysis, whereas the other was not predicted using our fusion detection analysis. 11 One of these tumors with papillary morphology also had copy number gain for chromosome 17.
Papillary Renal Cell Carcinoma, n = 2 Two tumors had morphology favoring papillary rather than clear cell renal cell carcinoma (Figures 1c and d ). Of these, 1 tumor (10 cm, pT2) had florid cytoplasmic vacuolization and copy number gain for chromosomes 7 and 17, supporting a papillary renal cell carcinoma with cytoplasmic clearing mimicking clear cell renal cell carcinoma. 13, 14 The second tumor was reported to be a mixture of 50% clear cell renal cell carcinoma and 50% papillary renal cell carcinoma, although the available whole-slide image demonstrated an entirely papillary architecture, consistent with papillary renal cell carcinoma. Therefore, it is possible that either sampling differences (due to two juxtaposed tumors) or areas of clear cell change within a papillary renal cell carcinoma tumor was confounding in this sample, causing the genetic data to reflect the typical pattern of papillary renal cell carcinoma.
Clear Cell Papillary Renal Cell Carcinoma, n = 1
Another tumor was composed of both solid and cystic components, fibrous stroma, and uniform lowgrade nuclei, together in support of clear cell papillary renal cell carcinoma [15] [16] [17] [18] ( Cancer Genome Atlas renal cell carcinoma L Favazza et al papillary renal cell carcinomas are typically regarded as having no VHL alterations, with rare exceptions in which classification is debatable [19] [20] [21] [22] [23] [24] ; however, few have been studied for promoter methylation. 17 
TCEB1 Mutant Renal Cell Carcinoma, n = 3
Three tumors harbored TCEB1 mutation, the features of which have recently been published by Hakimi et al. 6 Morphologically, these tumors have been noted to contain thick fibrous bands, a clear cell-like histological pattern, and voluminous cytoplasm (Figures 2a and b) . 6 
Other Histologies
After reclassification of the above 9 histological patterns, likely corresponding to distinct tumor entities, 18 tumors remained to be further investigated. Of these, distinct morphological categories were noted, as follows:
Renal cell carcinoma with fibromuscular stroma, n = 5. Five tumors exhibited prominent fibromuscular stroma (Figures 2c and d) . Three of these tumors were high-stage tumors (pT3), including 2 with metastasis and 1 with lymphovascular space invasion. Although Hakimi et al 6 recently reported that TCEB1 mutant renal cell carcinomas to have prominent fibromuscular stroma, this group of five tumors had a prominent fibromuscular component without TCEB1 mutation. Methylation data were available for four of these five tumors, of which three tumors showed no VHL promoter hypermethylation. One tumor demonstrated two of the three sites with promoter hypermethylation for VHL, which also harbored a SETD2 frameshift mutation. 3 High-grade renal cell carcinoma, n = 4. Four tumors were high-grade renal cell carcinomas with rhabdoid or sarcomatoid morphology ( Figure 3 ). One of these tumors was found to harbor a TP53 mutation and, as reported, was almost entirely sarcomatoid. Although TP53 mutations have been reported in clear cell renal cell carcinoma, 2 this alteration is also common in chromophobe renal cell carcinoma, 25 Cancer Genome Atlas renal cell carcinoma which despite its generally less aggressive behavior has a paradoxical predilection for sarcomatoid dedifferentiation. [26] [27] [28] Aberration in RB1 was also detected, which has been reported in chromophobe renal cell carcinoma. 29 Therefore, it is possible that this tumor represents chromophobe renal cell carcinoma in which the original histology is obscured by sarcomatoid features. A second tumor showed a SETD2 frameshift mutation, which is now recognized to be associated with clear cell renal cell carcinoma, although in the absence of VHL mutation and 3p deletion, it is uncertain whether this represents an alternative pathway to sarcomatoid renal cell carcinoma. 28 Methylation data were available for two of the four tumors, neither of which demonstrated VHL promoter hypermethylation. 3 Chromosome 3p loss present by karyotyping, n = 1. One tumor had an accompanying karyotype via conventional cytogenetic karyotyping, in which chromosome 3p deletion was noted in the original cytogenetic report. This tumor also harbored BAP1 mutation and had one of the three sites with VHL promoter hypermethylation.
VHL promoter hypermethylation, n = 1. An additional single tumor not discussed in any of the other categories exhibited widespread nuclear alignment, reminiscent of clear cell papillary renal cell carcinoma (Figure 4a ), 23 and was noted to have three sites of VHL promoter hypermethylation, in conjunction with MTOR mutation.
Tumors not reclassified. There remained in total 18 tumors not specifically reclassified (Figure 4 ) (as papillary renal cell carcinoma, TCEB1 mutant renal cell carcinoma, translocation renal cell carcinoma, or clear cell papillary renal cell carcinoma, including the 1 tumor for which the possibility of sarcomatoid chromophobe renal cell carcinoma was considered but not fully resolvable). Of these, 11 lacked a clear cell renal cell carcinoma-associated alteration (VHL promoter hypermethylation or PBRM1, SETD2, SMARCA4, or BAP1 alteration). From these, three were included in the fibromuscular stroma category, Cancer Genome Atlas renal cell carcinoma carcinoma had copy number increase for chromosome 7, suggesting trisomy 7; however, specific histological features of papillary renal cell carcinoma were not appreciable and immunohistochemical staining was not available. Of note, three additional tumors also had a similar copy number gain for chromosome 7, of which one had concurrent SETD2 frameshift mutation and was included in the high-grade renal cell carcinoma category, another had SETD2 frameshift mutation and was included in the fibromuscular stroma category, and the third was also included in the fibromuscular stroma category, with no other specific associated alterations. Other unusual findings in this group included foamy rather than empty-appearing cytoplasm (n = 1), intranuclear cytoplasmic invaginations (n = 1), and hyalinized stroma (n = 1); however, based on current morphological criteria these remained most in line with a diagnosis of clear cell renal cell carcinoma. Immunohistochemical results were not available on any of these five tumors, and in only one a conventional karyotype had been attempted but was unsuccessful.
Discussion
In this study, we sought to examine the histology of renal 'clear cell' tumors lacking the usual genetic characteristics of VHL and chromosome 3p abnormalities and attempted to assess whether as yet undefined subtypes of clear cell renal cell tumors exist. Existing data indicate that a majority of clear cell renal cell carcinoma tumors harbors chromosome 3p aberration and/or VHL mutation. 2, [30] [31] [32] However, it is also increasingly recognized that renal tumors are histologically and genetically complex, with a growing number of distinct tumor subtypes now recognized. 33, 34 As prototypical examples of this concept, translocation renal cell carcinomas, which are likely to have been often been diagnosed as clear cell renal cell carcinoma in the past, and the more recently recognized clear cell papillary renal cell carcinoma are now regarded as distinct tumor types with potential implications for patient management. Other emerging renal cell carcinoma subtypes, such as TCEB1 mutant renal cell carcinoma 6 and renal cell carcinoma with angioleiomyoma-like stroma (or renal angiomyoadenomatous tumor, among other names), 7, [35] [36] [37] [38] [39] illustrate that there may yet be other tumors historically considered clear cell renal cell carcinoma that are genetically and possibly prognostically distinct.
We found that, after critical histological review of tumors without chromosome 3p or VHL mutation, at least 9 of the 27 (33%) can likely be reclassified as distinct tumor histologies. These include three translocation renal cell carcinomas (as previously reported by Malouf et al 12 ), three TCEB1 mutant renal cell carcinomas (as recently characterized by Hakimi et al 6 ) , two papillary renal cell carcinomas, 13, 14 and one clear cell papillary renal cell carcinoma. 18, [40] [41] [42] Another 6 (22%) harbored additional clear cell renal cell carcinoma-associated gene alterations, including PBRM1, SETD2, SMARCA4, and BAP1. One of these was originally analyzed with conventional karyotype, which did detect 3p deletion, despite the absence of detected copy number change in the sequencing data. An additional tumor had VHL promoter hypermethylation, leaving only 11 tumors (2.6% of the original cohort of 418 tumors) that lacked clear cell renal cell carcinoma-associated genetic alterations and were not reclassifiable (4 tumors excluded, which had inadequate whole-slide images).
These results are strikingly similar to those of another recent study by Vang et al 43 evaluating highgrade ovarian serous carcinoma. The authors performed a histological review of all TP53 wild-type high-grade ovarian serous carcinoma from the Cancer Genome Atlas ovarian cancer specimens, 44 from which 96% of tumors harbored a TP53 genetic alteration. Of the TP53 wild-type tumors, alternative classifications were favored by at least a subset of the gynecological pathologists in essentially all cases, with exception of a rare tumor in which evolution from low-grade serous carcinoma was suspected. 43 This analysis led the authors to conclude that '... all de novo ovarian [high grade serous carcinomas] contain alterations of TP53...'. 43 One feature highlighted by this study is the presence of prominent fibromuscular stroma in renal cell tumors. Although Hakimi et al 6 recently characterized a subtly unique histology of renal cell carcinoma with TCEB1 mutation (mutually exclusive with VHL and 3p alteration) as containing thick fibromuscular bands, we also noted that 5 additional tumors from the 27 studied in this cohort exhibited prominent fibromuscular stroma in the absence of TCEB1 mutation. These also included aggressive histological and staging characteristics, findings that appear to be lacking in the few reported TCEB1 mutant tumors thus far, which are presently hypothesized to have a favorable prognosis. 6 One of these tumors also was noted to have VHL promoter hypermethylation and SETD2 frameshift mutation, likely supporting overall classification as a highgrade clear cell renal cell carcinoma. Similarly, in another recent study, almost half of renal cell carcinoma tumors originally considered renal cell carcinoma with angioleiomyoma-like stroma were ultimately excluded from the cohort after combined histological, immunohistochemical, and chromosomal analysis. 7 Therefore, despite the novel recognition of TCEB1 mutation in renal cell tumors, this appears not to be the only pathway to prominent fibromuscular stroma in renal cell carcinoma, some of which may be part of the spectrum of clear cell papillary renal cell carcinoma and others of which likely include unusual fibromuscular-appearing patterns of aggressive sarcomatoid renal cell carcinoma and reactive fibromuscular stroma from invasion of structures. 7 An additional four tumors in this cohort were high-grade or sarcomatoid renal cell carcinomas. In general, 'driver' alterations are often preserved in both the epithelial and sarcomatoid areas of sarcomatoid renal cell carcinoma. For example, Malouf et al 28 recently showed that VHL mutations are usually preserved in both the clear cell component and sarcomatoid component of the tumor. 28 Secondary clear cell renal cell carcinoma-associated mutations (for example BAP1, PBRM1, SETD2, SMARCD1, etc.) can also present in this setting. 28 In the four tumors that appeared to lack VHL and 3p alteration in this cohort, it remains to be better understood whether there are alternative pathways that progress directly to a more aggressive sarcomatoid phenotype rather than via evolution from usual low-grade renal cell carcinoma over time. For example, one tumor of these four demonstrated SETD2 frameshift mutation, despite absence of VHL alteration (although methylation data were not available for this specimen). This raises the question as to whether there are alternative pathways to highgrade sarcomatoid tumors that do not proceed through the same steps as usual clear cell renal cell carcinoma. 45 Alternatively, is it possible that the original alterations may be obscured by genomic instability or that detection may be influenced by variation across testing techniques. One other example from these four harbored TP53 and RB alterations with a completely sarcomatoid morphology in the available whole-slide image. Although these genetic alterations are not regarded as specific for a particular renal cell carcinoma histology, both are also known to occur in chromophobe renal cell carcinoma. 25, 29 Interestingly, despite the usually favorable prognosis of chromophobe renal cell carcinoma, this histology appears to have a paradoxical predilection for sarcomatoid dedifferentiation, [26] [27] [28] perhaps related to the enrichment of TP53 alteration. Therefore, it is possible that some extensively sarcomatoid renal cell carcinomas have actually evolved from chromophobe renal cell carcinoma and that the chromophobe component is not well visualized owing to sampling error, despite that clear cell renal cell carcinoma is much more common and may be the presumptive origin in diagnostic practice.
An additional interesting finding in this study is that two tumors previously characterized as harboring an SFPQ-TFE3 gene fusion by Malouf et al 12 had morphology indistinguishable from clear cell renal cell carcinoma, in combination with VHL mutation and copy number decrease for chromosome arm 3p. This is counterintuitive, as one might assume that these alterations are mutually exclusive. However, other unusual combinations of distinct presumptive 'driver' alterations have also been recently reported, such as in a recent study of tumors with both TFE3 translocation and SDHB mutation. 46 In this context, it remains to be better understood whether one alteration is the primary driver of tumorigenesis and the other is a secondary event due to genomic instability. 11 A limitation of our study is that only representative whole-slide images, typically from a single histological slide, were available for review. In practice, we would typically regard a tumor as clear cell renal cell carcinoma if low-grade areas with prototypical morphology are present, even if other areas exhibit high-grade, heterogeneous, or unusual morphology. 47 Therefore, owing to sampling error, low-grade areas with a classic appearance may have been missed in a subset of the cases with negative genetics. However, the striking predilection for VHL and 3p alterations suggests that alternative molecular mechanisms and classification possibilities should be considered in tumors considered 'clear cell renal cell carcinoma' lacking these findings, which might then have implications for the efficacy of usual clear cell renal cell carcinoma-targeted therapies.
Additionally, ancillary techniques, such as immunohistochemistry (n = 4) and conventional karyotyping (n = 3), were available only in a small subset of cases. Notably, however, each of the three tumors karyotyped had a significant finding, including one in which 3p deletion was detected by karyotype but not by copy number analysis. Therefore, owing to limitations and variations between testing methodology (karyotype, FISH, sequencing, methylation analysis, and others), an even larger number of the genetically 'negative' tumors may have harbored a chromosomal alteration if karyotyped, which would even further reduce the percentage of 3p intact clear cell renal cell carcinoma tumors. As an illustration of these potential differences between techniques, only 20 tumors lacking VHL mutation or deep deletion appeared to have copy number loss from the entire chromosome 3 based on our review of http://cbioportal.org data, whereas other studies using cytogenetic karyotyping have suggested that monosomy 3 may be a relatively common mechanism of chromosome 3 loss in clear cell renal cell carcinoma. 48 Conversely, although 3p arm loss is a hallmark of clear cell renal cell carcinoma, it may not be entirely specific for clear cell renal cell carcinoma, as it has been reported in papillary renal cell carcinoma with clear cell change and the recently described renal cell carcinomas with TFEB amplification. 11, 13 
Conclusions
The vast majority of clear cell renal cell carcinomas harbor VHL mutation, 3p copy number loss, or both, suggesting that these may be defining abnormalities. Of tumors with clear cell histology that lack these alterations, a significant fraction can likely be reclassified as established and emerging entities. The significance of concurrent gene fusion (such as TFE3 rearrangement) and VHL mutation or 3p arm deletion in the same tumor remains to be better understood. The remaining tumors suggest that a 'clear cell' appearance may be a common phenotype of several genetic pathways, for which improved understanding may define new entities and guide prognostication and treatment.
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